About antazoline hydrochloride
Antazoline hydrochloride manufacturers mainly supply eye drop makers, such as the producers of Spersallerg, while Polfa Warszawa makes the injectable antazoline mesylate (Phenazolinum) in Poland. Antazoline is a first-generation antihistamine. As the hydrochloride, it is used in eye drops for allergic conjunctivitis, usually with a decongestant. As the mesylate injection, it is used in Poland for allergic emergencies and to restore normal rhythm in atrial fibrillation. Pharmaceutical companies can source antazoline eye drops, injection and API through out-licensing, supply or technology transfer.
Antazoline hydrochloride key facts
|
Property |
Antazoline hydrochloride |
|---|---|
|
INN |
Antazoline (as hydrochloride; also mesylate and phosphate salts) |
|
Chemical name |
N-benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline |
|
Molecular formula / weight |
C17H19N3 / 265.4 g/mol (base) |
|
CAS number |
2508-72-7 (hydrochloride) |
|
ATC code |
R06AX05 |
|
Drug class |
H1 antihistamine (ethylenediamine type); antiarrhythmic effect (injection) |
|
Eye drop brand |
Spersallerg: antazoline hydrochloride 0.5 mg/ml + tetryzoline hydrochloride 0.4 mg/ml |
|
Eye drop markets |
Switzerland, Poland, Czech Republic, Slovakia, Romania, Bulgaria, South Africa, Taiwan, Hong Kong and others |
|
Injection brand |
Phenazolinum (antazoline mesylate) 50 mg/ml, Polfa Warszawa, Poland |
|
Indications (eye drops) |
Allergic conjunctivitis and eye irritation with redness |
|
Indications (injection) |
Acute allergic conditions with adrenaline; paroxysmal supraventricular arrhythmias, including atrial fibrillation |
|
Historical products |
Antistin-Privin (with naphazoline); Vasocon-A (US, with naphazoline) |
|
Patent status |
Off-patent |
Antazoline hydrochloride manufacturers and licensing history
Antazoline is an old antihistamine, originally sold as Antistin. It became widely used in eye drops combined with a decongestant, such as naphazoline (Antistin-Privin) or tetryzoline (Spersallerg). Spersallerg, with 0.5 mg/ml antazoline hydrochloride and 0.4 mg/ml tetryzoline, is registered in many countries in Europe, Asia, the Middle East and Africa.
In Poland, Polfa Warszawa makes Phenazolinum, an antazoline mesylate injection. Its antiarrhythmic effects were first described in the 1960s. It is now widely used in Polish emergency departments to restore normal rhythm in recent-onset atrial fibrillation, supported by registry studies (CANT) and a randomised trial against propafenone (AnProAF, 2024).
Antazoline API is produced by a small number of companies. Buyers should confirm the salt form (hydrochloride, mesylate or phosphate), GMP status and suitability for sterile eye drops or injection before choosing a supplier.
Antazoline hydrochloride dosage forms and dossier types
Antazoline is supplied as eye drops (hydrochloride, in combination) and as injection (mesylate). Most licensing interest is in combination eye drops.
|
Form |
Strengths |
Typical dossier |
Notes |
|---|---|---|---|
|
Antazoline / tetryzoline eye drops |
0.5 mg/ml + 0.4 mg/ml |
EU national dossier |
Main form for licensing; reference Spersallerg |
|
Antazoline / naphazoline eye drops |
Per national MA |
National dossier |
Antistin-Privin type products |
|
Antazoline mesylate injection |
50 mg/ml (100 mg/2 ml) |
Polish national dossier |
Reference Phenazolinum |
|
Antazoline API |
Bulk |
DMF |
Hydrochloride, mesylate or phosphate |
|
Target market |
Dossier format |
Key requirement |
|---|---|---|
|
European Union |
National dossier |
Reference Spersallerg; sterile ophthalmic manufacturing |
|
Poland |
National dossier |
Phenazolinum injection for arrhythmia and allergy |
|
Asia, Middle East, Africa |
National CTD |
Spersallerg widely registered |
Antazoline hydrochloride regulatory and patent status
Antazoline is off-patent. Antazoline and tetryzoline eye drops are authorised nationally in many countries, often without prescription. Phenazolinum injection is authorised in Poland for allergic emergencies and supraventricular arrhythmias. Antazoline is not included in major international atrial fibrillation guidelines, although Polish studies support its use for cardioversion.
Antazoline hydrochloride mechanism of action and therapeutic use
Antazoline blocks histamine H1 receptors, which reduces itching, redness and swelling in allergic conjunctivitis. In eye drops, it is combined with a decongestant that narrows blood vessels and reduces redness. Given intravenously, antazoline also has quinidine-like antiarrhythmic effects, which can restore normal rhythm in recent-onset atrial fibrillation.
Antazoline hydrochloride licensing and sourcing
Antazoline suppliers and licensing partners typically offer dossier out-licensing, finished-product supply or technology transfer. Buyers usually compare GMP status (EU GMP, WHO GMP), sterile manufacturing capability, salt form and territory availability. Current offers and supplier contacts are listed among the antazoline hydrochloride manufacturers on Pipelinepharma.
Frequently asked questions about antazoline hydrochloride
Who are the main antazoline manufacturers? Spersallerg eye drops, with antazoline hydrochloride and tetryzoline, are registered in many countries. Polfa Warszawa makes Phenazolinum injection (antazoline mesylate) in Poland.
What is antazoline hydrochloride used for? Antazoline hydrochloride is used in eye drops for allergic conjunctivitis, combined with a decongestant such as tetryzoline or naphazoline.
Is antazoline used for atrial fibrillation? Yes, in Poland. Antazoline mesylate injection (Phenazolinum) is used to restore normal rhythm in recent-onset atrial fibrillation.
What forms and strengths of antazoline are available? Antazoline is available as eye drops (0.5 mg/ml with 0.4 mg/ml tetryzoline in Spersallerg) and as a 50 mg/ml injection of antazoline mesylate.
Is an antazoline eye drop dossier available for licensing? Yes. Antazoline and tetryzoline eye drop dossiers can be licensed in national formats, referencing Spersallerg.
Popular Searches
Want unlimited access to the Pipelinepharma database?
Become a subscriber to unlock:
-
Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.
-
Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.
-
Higher profitability: compare multiple supplier offers and secure the best commercial terms.
-
Expanded network: view supplier portfolios and stay updated on new products.
-
Value-added product ideas: discover products with lower competition potential.
-
Access to marketing authorizations for sale: find already registered products in your target markets.